Group items tagged

Ethical Considerations in the Interpretation and Communication of Clinical Trial Results -- Coultas 4 (2): 194 -- Proceedings of the American Thoracic Society

Journal of Skin CancerVolume 2011 (2011), Article ID 571734, 6 pagesdoi:10.1155/2011/571734 © 2011 Mary H. Lien and Vernon K. Sondak.

Fewer than half of all clinical trials recently published in journals with high impact factors are adequately registered, and about a third of those that are registered properly show discrepancies between the registered primary outcome and the one that actually gets reported.

Percutaneous coronary intervention (PCI) can often be deferred in patients with stable coronary artery disease (CAD) and significant coronary lesions without adding risk while optimal medical therapy (OMT) is given a chance to work, and it can be consider

Abbott Announces Positive Six-Month Results from the World's First Clinical Trial of A Fully Bioabsorbable Drug-Eluting Coronary Stent\nAbbott's Bioabsorbable Stent Technology Holds Promise as Future-Generation Treatment Option for Physicians Treating Pati

Downloadable slideshows from this November 2007 conference. For report PDFs: (1) http://is.gd/3AoNu (2) http://is.gd/3AoXG

The fact that an increasing number of medications are unable to beat sugar pills has thrown the industry into crisis. It's not that the old meds are getting weaker, drug developers say. It's as if the placebo effect is somehow getting stronger. Why are inert pills suddenly overwhelming promising new drugs and established medicines alike? Pharma doesn't know, and drugmakers are realizing they need to fully understand the mechanisms behind it so they can design trials that differentiate more clearly between the beneficial effects of their products and the body's innate ability to heal itself. special task force of the Foundation for the National Institutes of Health is seeking to stem the crisis by quietly undertaking one of the most ambitious data-sharing efforts in the history of the drug industry.